Experience of using rifapentine in continuation phase of treatment of adult tuberculosis cases
https://doi.org/10.21292/2075-1230-2019-97-6-31-35
Abstract
The objective of the study: to estimate efficacy and safety of the drug of rifapentine in continuation phase of chemotherapy in adults suffering from pulmonary tuberculosis.
Subjects and methods. 66 HIV negative pulmonary tuberculosis patients transferred to continuation phase of treatment with regimens I and III were enrolled in a prospective randomized trial. The patients were randomly divided into 2 groups. Group I included 36 of patients who were prescribed with rifapentine at the dose of 10 mg per 1 kg of body mass, 3 of times per week, and isoniazid at the dose 10 mg per 1 kg of body mass daily. Group II included 30 of patients who were prescribed with rifampicin 450-600 mg/day (taking into account the body mass) and isoniazid, 10 mg per 1 kg of body mass daily. In continuation phase of treatment, patients from both groups received 120 doses of drugs.
Results. 1. In continuation phase of chemotherapy in new pulmonary tuberculosis adult cases, the regimen consisting of rifapentine + isoniazid demonstrated the efficacy compatible with the one of the regimen consisting of rifampicin + isoniazide.
2. Use of rifapentine at the dose of 10 mg/kg, 3 times a week in continuation phase of treatment did not cause an increase in adverse events compared to daily in-take of rifampicin.
3. The anti-tuberculosis drug of rifapentine can successfully be used in continuation phase of chemotherapy in drug susceptible tuberculosis patients.
4. The prescription of rifapentine reduces the drug burden since it can be taken 3 times a week.
About the Authors
T. I. Morozova
Saratov State Medical University named after V. I. Razumovsky
Russian Federation
Russian Federation
Tatyana I. Morozova - Doctor of Medical Sciences, Professor, Head of Phthisiology Department.
112, B. Kazachya St., Saratov, 410012, Phone/Fax: +7 (8452) 26-16-90; +7 (8452) 26-16-90.
O. N. Otpuschennikova
Saratov State Medical University named after V. I. Razumovsky
Russian Federation
Russian Federation
Olga N. Otpuschennikova - Candidate of Medical Sciences, Associate Professor of Phthisiology Department.
112, B. Kazachya St., Saratov, 410012, Phone/Fax: +7 (8452) 26-16-90; +7 (8452) 26-16-90.
References
1. Klinicheskie rekomendatsii. Tuberkulez organov dykhaniya u vzroslykh. [Clinical recommendations. Respiratory tuberculosis in adults]. 2018, Available: http://cr.rosminzdrav.ru/#!/schema/943 (Accessed as of 24.04.2019).
2. Litvinova N.V., Ivanushkina T.N., Slogotskaya L.V., Ivanova D.А., Borisov S.E. Safety and efficacy of rifapentine in the treatment of drug susceptible respiratory tuberculosis. Tuberculosis and Lung Diseases, 2014, vol. 91, no. 4, pp. 46-53. (In Russ.)
3. Samoylova А.G., Veselova E.I., Lovacheva O.V., Kaminskiy G.D. The anti-tuberculosis antibiotic of rifapentine: perspectives of clinical use. Tuberculosis and Lung Diseases, 2018, vol. 96, no. 12, pp. 55-59. (In Russ.)
4. Sokolova G.B., Krasnov V.А., Reykhrud T.А., Tsibanev А.А. The new anti-tuberculosis drug of Rifapex. Tuberculosis and Lung Diseases, 2009, vol. 86, no. 11, pp. 61-64. (In Russ.)
5. Federalnye klinicheskie rekomendatsii po profilaktike, diagnostike i lecheniyu tuberkuleza u bolnykh VICH-infektsiey. [Federal clinical recommendations on prevention, diagnostics and treatment of tuberculous in HIV patients]. 2016, Available: http://roftb.ru/netcat_files/doks2016/rec2016.pdf (Accesed as of 16.04.2019 г.).
6. Benator D., Bhattacharya M. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomized clinical trial. Lancet, 2002, vol. 360, pp. 528-534.
7. Bock N.N., Sterling T.R., Hamilton C.D., Pachucki C., Wang Y.C., Conwell D.S., Mosher A., Samuels M., Vernon A. and the Tuberculosis Trials Consortium. A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment. Am. J. Respir. Crit. Care Med., 2002, no. 165, pp. 1526-1530.
8. Chunlan Zheng, Xiufen Hu, Li Zhao, Minhui Hu, Feng Gao Clinical and pharmacological hallmarks of rifapentine’s use in diabetes patients with active and latent tuberculosis: do we know enough? Dove Medical Press Limited, 2017, no. 11, pp. 2957-2968.
9. Dorman S.E., Savic R.M., Goldberg S., Stout J.E., Schluger N., Muzanyi G., Johnson J.L., Nahid P., Hecker E.J., Heilig C.M., Bozeman L., Feng P.J., Moro R.N., MacKenzie W., Dooley K.E., Nuermberger E.L., Vernon A., Weiner M. Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial. Send to Am. J. Respir. Crit. Care Med., 2015, vol. 191, no. 3, pp. 333-343.
10. Gao X.F., Li J., Yang Z.W. et al. Rifapentine vs. rifampicin for the treatment of pulmonary tuberculosis: a systematic review. Int. J. Tuberc. Lung Dis., 2009, vol. 13, no. 7, pp. 810-819.
11. Marcus Conde B., Mello F.C., Duarte R.S., Cavalcante S.C., Rolla V., Dalcolmo M., Loredo C., Durovni B., Armstrong D.T., Efron A., Barnes G.L., Marzinke M.A., Savic R.M., Dooley K.E., Cohn S., Moulton L.H., Chaisson R.E., Dorman S.E. A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis. Cond. PLoS One, 2016, vol. 11, no. 5, pp. e0154778. Published online 2016 May 9.
12. Sonal S. Munsiff Chrispin Kambili Shama Desai Ahuja Rifapentine for the Treatment of Pulmonary Tuberculosis. Clin. Infect. Dis., 2006, vol. 43, is. 11, pp. 1468-1475.
13. Tam C.M., Chan S.L., Lam C.W., Leung C.C., Kam K.M., Morris J.S., Mitchison D.A. Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis: initial report. Am. J. Respir. Crit. Care Med., 1998, no. 157, pp. 1726-1733.
Review
For citations:
Morozova T.I., Otpuschennikova O.N. Experience of using rifapentine in continuation phase of treatment of adult tuberculosis cases. Tuberculosis and Lung Diseases. 2019;97(6):31-35. (In Russ.) https://doi.org/10.21292/2075-1230-2019-97-6-31-35
Views:
1046
Email this article 